Cargando…
Impact of the faecal immunochemical test on colorectal cancer survival
BACKGROUND: There is already evidence that the faecal immunochemical test (FIT) is a useful tool for the diagnosis of colorectal cancer (CRC) that helps to identify symptomatic patients requiring early colonoscopy. Although the recommendation to use FIT is widely accepted, there are no data concerni...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7328266/ https://www.ncbi.nlm.nih.gov/pubmed/32611328 http://dx.doi.org/10.1186/s12885-020-07074-y |
_version_ | 1783552703681527808 |
---|---|
author | Gutierrez-Stampa, María Angeles Aguilar, Vanessa Sarasqueta, Cristina Cubiella, Joaquín Portillo, Isabel Bujanda, Luis |
author_facet | Gutierrez-Stampa, María Angeles Aguilar, Vanessa Sarasqueta, Cristina Cubiella, Joaquín Portillo, Isabel Bujanda, Luis |
author_sort | Gutierrez-Stampa, María Angeles |
collection | PubMed |
description | BACKGROUND: There is already evidence that the faecal immunochemical test (FIT) is a useful tool for the diagnosis of colorectal cancer (CRC) that helps to identify symptomatic patients requiring early colonoscopy. Although the recommendation to use FIT is widely accepted, there are no data concerning whether this strategy improves patient survival.The objective was to assess whether the survival is higher if CRC patients have been first diagnosed by FIT (as compared with the rest of patients with CRC). METHODS: We identified all cases of CRC diagnosed between 2009 and 2016 in Donostialdea (Spain), excluding all the CRC detected in population screening. We focused on symptomatic patients. One thousand five hundred twenty-seven cases of CRC were divided into two groups based on the route to diagnosis: group 1: individuals who tested positive in a FIT during the year before diagnosis, and group 2: others.Survival was assessed by Kaplan-Meier estimation, and with the log-rank test. A Cox regression model was used to adjust for differences between groups due to other variables associated with survival. RESULTS: One thousand nine hundred sixty-seven cases of invasive CRC were identified, of which 22.4% were detected in population screening. Of the 1527 cases diagnosed in symptomatic patients, 317 patients had undergone a FIT in the year before the diagnosis of CRC. In 279 cases(18.3%), the result had been positive and this was the first step towards their CRC diagnosis (group 1). Group 2 was composed of the 1248 cases of CRC (81.7%). Considering these cases, 1210 patients with CRC did not undergo any FIT while 38 patients presented a negative result in the year before the diagnosis. The rate of early-stage disease (stage I or II) was higher in group 1 (51.3% vs 45.5% in group 2) (p = 0.04). Furthermore, the 3-year survival was longer in group 1 (72% vs 59% in group 2) (HR 1.50; 95% CI 1.22–1.84).The variables independently associated with worse survival were: group 2, age > 70 years and stage at the moment of diagnosis. CONCLUSIONS: The use of FIT as a diagnostic strategy in symptomatic patients may improve survival in CRC. Nonetheless,FIT is still not widely used in our region. |
format | Online Article Text |
id | pubmed-7328266 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-73282662020-07-02 Impact of the faecal immunochemical test on colorectal cancer survival Gutierrez-Stampa, María Angeles Aguilar, Vanessa Sarasqueta, Cristina Cubiella, Joaquín Portillo, Isabel Bujanda, Luis BMC Cancer Research Article BACKGROUND: There is already evidence that the faecal immunochemical test (FIT) is a useful tool for the diagnosis of colorectal cancer (CRC) that helps to identify symptomatic patients requiring early colonoscopy. Although the recommendation to use FIT is widely accepted, there are no data concerning whether this strategy improves patient survival.The objective was to assess whether the survival is higher if CRC patients have been first diagnosed by FIT (as compared with the rest of patients with CRC). METHODS: We identified all cases of CRC diagnosed between 2009 and 2016 in Donostialdea (Spain), excluding all the CRC detected in population screening. We focused on symptomatic patients. One thousand five hundred twenty-seven cases of CRC were divided into two groups based on the route to diagnosis: group 1: individuals who tested positive in a FIT during the year before diagnosis, and group 2: others.Survival was assessed by Kaplan-Meier estimation, and with the log-rank test. A Cox regression model was used to adjust for differences between groups due to other variables associated with survival. RESULTS: One thousand nine hundred sixty-seven cases of invasive CRC were identified, of which 22.4% were detected in population screening. Of the 1527 cases diagnosed in symptomatic patients, 317 patients had undergone a FIT in the year before the diagnosis of CRC. In 279 cases(18.3%), the result had been positive and this was the first step towards their CRC diagnosis (group 1). Group 2 was composed of the 1248 cases of CRC (81.7%). Considering these cases, 1210 patients with CRC did not undergo any FIT while 38 patients presented a negative result in the year before the diagnosis. The rate of early-stage disease (stage I or II) was higher in group 1 (51.3% vs 45.5% in group 2) (p = 0.04). Furthermore, the 3-year survival was longer in group 1 (72% vs 59% in group 2) (HR 1.50; 95% CI 1.22–1.84).The variables independently associated with worse survival were: group 2, age > 70 years and stage at the moment of diagnosis. CONCLUSIONS: The use of FIT as a diagnostic strategy in symptomatic patients may improve survival in CRC. Nonetheless,FIT is still not widely used in our region. BioMed Central 2020-07-01 /pmc/articles/PMC7328266/ /pubmed/32611328 http://dx.doi.org/10.1186/s12885-020-07074-y Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Article Gutierrez-Stampa, María Angeles Aguilar, Vanessa Sarasqueta, Cristina Cubiella, Joaquín Portillo, Isabel Bujanda, Luis Impact of the faecal immunochemical test on colorectal cancer survival |
title | Impact of the faecal immunochemical test on colorectal cancer survival |
title_full | Impact of the faecal immunochemical test on colorectal cancer survival |
title_fullStr | Impact of the faecal immunochemical test on colorectal cancer survival |
title_full_unstemmed | Impact of the faecal immunochemical test on colorectal cancer survival |
title_short | Impact of the faecal immunochemical test on colorectal cancer survival |
title_sort | impact of the faecal immunochemical test on colorectal cancer survival |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7328266/ https://www.ncbi.nlm.nih.gov/pubmed/32611328 http://dx.doi.org/10.1186/s12885-020-07074-y |
work_keys_str_mv | AT gutierrezstampamariaangeles impactofthefaecalimmunochemicaltestoncolorectalcancersurvival AT aguilarvanessa impactofthefaecalimmunochemicaltestoncolorectalcancersurvival AT sarasquetacristina impactofthefaecalimmunochemicaltestoncolorectalcancersurvival AT cubiellajoaquin impactofthefaecalimmunochemicaltestoncolorectalcancersurvival AT portilloisabel impactofthefaecalimmunochemicaltestoncolorectalcancersurvival AT bujandaluis impactofthefaecalimmunochemicaltestoncolorectalcancersurvival |